everybody throughout the United States, including physicians, are aware of sarcomas and aware that you can, in the majority of cases, save extremities. Often, the patient might go to another type of doctor and they say you are probably going to need an amputation, but then the patient ends up seeing an orthopedic oncologist, and the extremity can be saved," Dr. Wittig said in a telephone interview after the meeting.
Because sarcomas are more prominent in adolescents, they are often misdiagnosed by generalists as sports-related injuries, bruises, or hematomas, resulting in delayed diagnoses, Dr. Wittig said. But, when sarcomas are identified as a tumor, approximately 95% of patients can be successfully treated with bone-sparing surgery.
Phases of Limb-Sparing Procedure
Much of the success in limb-sparing surgery can be attributed to the increasing use of induction chemotherapy, which kills tumors preoperatively, allowing for easier tumor resection and softtissue preservation, and advanced imaging tools such as magnetic resonance imaging, which allows surgeons to plan operations better by knowing the exact extent of the tumor and whether or not the neurovascular structures are involved or directly encased by the neoplasm, Dr. Wittig said.
The most common sites for osteosarcomas are the distal and proximal femur and proximal humerus, which along with total femur replacements have a 10-year survival rate of more than 90%.
In a follow-up study several years ago of 110 patients who underwent distal resection with endoprosthetic reconstruction, the overall limb-salvage rate was 96%, and 85% of patients had what was considered excellent results at two years.
"For prosthetic replacements in the distal femur you have virtually normal knee function, and you can barely tell the difference from side to side in normal knee patients," Dr. Wittig noted.
Infection did develop in 5% of patients, meaning that the prosthesis may need revision, and local recurrence occurred in another 5% of patients, who could either undergo resection again or amputation.
The proximal tibia, which is the site for about 20% of osteosarcomas, is associ- some 2,000 medicines. Included in the list are the following medicines in development for prevention of cancer-related osteoporosis and treatment of cancer-related pain. The chart shows the name of each product, the sponsor, the product category, the indication, the development status as of the time of the report in November, and contact information. The full report also includes drugs for more general conditions relevant to cancer patients, such as depression; bladder/kidney, gastrointestinal, lung/respiratory, and sleep disorders; prostate disease; sepsis; sexual dysfunction; and skin conditions.
Development Product Name Sponsor Indication Status
Because sarcomas are more prominent in adolescents, they are often misdiagnosed by generalists as sports-related injuries, bruises, or hematomas, resulting in delayed diagnoses.
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JAMES C. WITTIG, MD: "If you follow the general principles of first resecting the tumor according to oncological principles and separating the neurovascular structures and reconstructing the skeletal defect and really pay attention to the soft tissues, you should have good outcomes in the majority of cases."
continued on page 28 ated with a slightly lower 10-year survival rate of 65% because of the absence of sufficient soft tissue at the location as well as higher rates of infection due to lower vascularity in the area. The most important factors for a successful surgery are that the biopsy be performed in the proper manner and that all bone sarcoma surgeries take place in three main steps, Dr. Wittig said.
"Inappropriately performed biopsy where there is extensive contamination of the surrounding soft tissues or extensive contamination of the neurovascular structures is probably the number one reason amputations are performed nowadays, and it is very important that the biopsy be performed by the surgeon who will perform the definitive procedure or by a radiologist who is in direct communication with the surgeon to appropriately plan the exact tract of the biopsy."
The three phases of the limbsparing procedure are to:
• Remove the tumor.
• Fix the skeletal defect.
• Reconstruct the muscle.
Removing the tumor requires extensive preoperative planning with appropriate tests such as MRI or CT, and involves separating the mass from important neurovascular structures and muscles that need to be preserved in order to salvage the extremity, he said.
Secondly, the skeletal defect must be fixed by replacing the bone in the joint, and the third and final step is to reconstruct the muscles and cover the prosthesis, making sure to rotate muscles for function and for coverage of the prosthetic replacement.
"If you follow the general principles of first resecting the tumor according to oncological principles and separating the neurovascular structures and reconstructing the skeletal defect and really paying attention to the soft tissues you should have good outcomes in the majority of cases," Dr. Wittig said.
Indications for Amputation
Despite the favorable odds of a successful bone-sparing surgery, there are some instances when a patient may need an amputation, Dr. Wittig said.
Some indications for amputation are tumor fungation, infection, and pathologic fracture, which Dr. Wittig noted is a relative contraindication.
"Often patients who develop a pathologic fracture can be mobilized and treated with induction chemotherapy and if they have a good response indicated by the pathologic fracture healing, you can probably perform a safe limb-sparing procedure, and survival is probably not compromised."
Other indications include a massive tumor size, neurovascular involvement in which the tumor is wrapped around the neurovascular structure, poor biopsy, tumor progression on chemotherapy, skeletally immature patients, and patients who have had previous radiation or chemotherapy.
To prevent patients from having a limb amputated, proper triage is key, noted the moderator of the session at which Dr. Wittig spoke, Gustavo Del Toro, MD, Director of the Pediatric Hematopoietic Cell Transplantation Service in the Jack Martin Division of Pediatric Hematology/ Oncology at Mount Sinai Hospital in New York City.
"The most important thing is that, from the get go, these patients be put into the hands of surgeons who have experience with these diseases and that the initial surgical approach is done by experienced hands in the most appropriate way," Dr. Del Toro said in a telephone interview after the meeting.
And Dr. Wittig noted that even with the improvements in surgical technique and the development of better prosthetic replacements, there still will be some patients who will ultimately undergo amputations many years later because the replacements wear over time.
"We need more investigation into how we can stimulate wounds to heal better and muscles to reattach to prosthetic devices better and better prosthetic devises that don't loosen and do not fail over the course of time from breaking or from loosening." O T
